- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01219790
ZOLEDRONIC ASSOCIATED With Hight Hypofractionated Radiotherapy Dose in Bone Metastases Vertebral Prostate Adenocarcinoma (GEMO)
STUDY OF PHASE ID'ACIDE ZOLEDRONIC ASSOCIATED WITH A STRONG DOSE Hypofractionated Radiotherapy in Bone Metastases Vertebral Prostate Adenocarcinoma
This study will determine the delayed neurotoxicity (12 months) of a hypofractionated high dose irradiation (3 Gy x 9) associated with zoledronic acid.
The administration of zoledronic acid repeat dosages defined under the Authorisation on the Market.
All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
-
Angers, Frankrike, 49000
- Centre Paul Papin
-
Lyon, Frankrike, 69000
- Centre Leon Berard
-
Saint Herblain, Frankrike, 44805
- Centre Rene Gauducheau
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
Adenocarcinoma of the prostate metastatic Age> 18 years3.
- Life expectancy> 12 months;
- Performance Index status <3 PSA ≥ 4 ng / ml Zoledronic acid treatment in progress as recommended by the Authority for the Marketing Creatinine clearance above 30 ml / min Lack of maintenance causing disabling pain not lying down long (30 minutes) No history of radiotherapy to the region to be irradiated Absence of neurological signs compression Distance between the metastasis and spinal cord ≥ 5 mm Absence of metastases unstable metastatic epidural spinal cord compression or may require surgery before radiotherapy
Exclusion Criteria:
- Concomitant treatment with a drug testing, participation in another clinical trial within <30 days
- Presence of central system nervous desease (symptoms or progressive), Patient with a severe neurological disease, current manifestations of peripheral neuropathy> grade 2 NCI-CTC V4 Existence of another severe pulmonary disease, liver or kidney, digestive likely to be exacerbated by treatment,
- Untreated with zoledronic acid
- Treatment with a bisphosphonate other than Zoledronic acid
- Clinically significant hypersensitivity to zoledronic acid, other bisphosphonates or to any excipients in the formulation of Zometa.
- Creatinine clearance below 30 ml / min
- History of another primary cancer (except basal cell skin cancer)
- Or demented patient with altered mental status who can not obtain informed consent. / Persons deprived of liberty or under guardianship
- Pain not resulting in maintaining the prolonged supine position (30 minutes)
- PSA below 4 ng / ml
- History of radiotherapy in localized tumor site
- Distance between the metastasis and spinal cord <5 mm
- Monitoring impossible because of psychological, sociological or because of geographical distance.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: irradiation + zometa
|
All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
The administration of zoledronic acid as defined under the Authorisation on the Market.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Neurological toxicity was defined as NCI-CTC grade V4.de greater than 2.
Tidsramme: 12 months
|
12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- BRD 10/2-S
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på external radiotherapy
-
Guohua ZengUkjent
-
David Grant U.S. Air Force Medical CenterTilbaketrukketHjerte-og karsykdommer | LungesykdomForente stater
-
Chi-Ming ChuDr. Chiang, Shang-lin; Dr. Liang-Cheng ChenRekrutteringHjerteutfall | Enhanced External Counterpulsation (EECP) | HjertekraftindeksTaiwan
-
Baxter Healthcare CorporationDuke UniversityRekruttering
-
West China HospitalSichuan Provincial People's Hospital; The First People's Hospital of Ziyang og andre samarbeidspartnereHar ikke rekruttert ennå
-
University Hospital HeidelbergRekruttering
-
Saluda Medical Pty LtdFullført
-
Universitas PadjadjaranRekrutteringAngina pectoris | MotpulseringIndonesia
-
National Cardiovascular Center Harapan Kita Hospital...UkjentHjerterehabilitering | Angiogenese | Ildfast anginaIndonesia
-
Cancer Institute and Hospital, Chinese Academy...Sun Yat-sen UniversityUkjentLymfom, stor B-celle, diffusKina